Monte Moore
Psychiatric/Mental Health, Child & Family · Ruston, LANPI 1558829382
Payments from drug & device makers
Across 160 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$493
- Axsome Therapeutics, Inc.$473
- Supernus Pharmaceuticals, Inc.$271
- Alkermes, Inc.$269
- Tris Pharma Inc$98
- plus $446 from 12 others
What the payments were for
- Food & beverage$3,438100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $1,393 |
| Johnson & Johnson | 37 | $493 |
| Axsome Therapeutics, Inc. | 8 | $473 |
| Supernus Pharmaceuticals, Inc. | 7 | $271 |
| Alkermes, Inc. | 3 | $269 |
| Tris Pharma Inc | 6 | $98 |
| Corium, LLC | 10 | $92 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Ironshore Pharmaceuticals Inc. | 4 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $40 |
| Merck | 2 | $40 |
| Vertex | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| GSK | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Indivior Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few psychiatric/mental health, child & family providers in Louisianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 112 | $169,940 |
| AristadaAripiprazole Lauroxil | 20 | $58,369 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $15,487 |
| VyvanseLisdexamfetamine Dimesylate | 32 | $11,068 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 291 | $10,477 |
| Atomoxetine Hcl | 53 | $6,578 |
| Buprenorphine Hcl | 100 | $5,974 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 101 | $5,949 |
| Lisdexamfetamine Dimesylate | 24 | $4,010 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 38 | $3,932 |
| Guanfacine Hcl ErGuanfacine Hcl | 82 | $2,971 |
| Enbrace HrMultivit41/Iron/Folate8/Ps-Dha | 20 | $2,770 |
| Trazodone Hcl | 73 | $2,146 |
| Bupropion XlBupropion Hcl | 68 | $1,213 |
| Gabapentin | 53 | $1,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,393 | $169,940112 claims |
| Alkermes, Inc.Aristada | $269 | $58,36920 claims |
| Axsome Therapeutics, Inc.Auvelity | $473 | $15,48718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $16 | $11,06832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, child & family providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.